Literature DB >> 16618517

Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.

John Willy Haukeland1, Jan Kristian Damås, Zbigniew Konopski, Else Marit Løberg, Terese Haaland, Ingeborg Goverud, Peter A Torjesen, Kåre Birkeland, Kristian Bjøro, Pål Aukrust.   

Abstract

BACKGROUND/AIMS: To elucidate the role of systemic inflammation in nonalcoholic fatty liver disease (NAFLD).
METHODS: Serum samples in 47 patients with histologically verified NAFLD (22 with simple steatosis and 25 with nonalcoholic steatohepatitis [NASH]), and in 30 age-, sex- and ethnicity-matched healthy controls, were assessed for (i) general markers of inflammation (C-reactive protein [CRP], tumor necrosis factor [TNF]-alpha, and interleukin [IL]-6), (ii) chemokines (CC-chemokine ligand [CCL] 2/monocyte chemoattractant protein [MCP]-1, CCL19 and CCL21), (iii) adipocytokines related to insulin resistance and inflammation (adiponectin and leptin) and (iv) a marker of oxidative stress (8-isoprostane-F2alpha).
RESULTS: Serum levels of several inflammatory cytokines were increased in NAFLD as compared to controls, and IL-6 (P=0.017), CCL2/MCP-1 (P=0.008) and CCL19 (P=0.001), but not CRP (P=0.199), remained elevated also after correction for sex, body mass index (BMI) and age. Comparing NASH with simple steatosis, levels of TNF-alpha (P=0.024) and CCL2/MCP-1 (P=0.012) were elevated and adiponectin (in women) (P=0.001) were decreased also after adjustment for sex, BMI and presence of the metabolic syndrome.
CONCLUSIONS: Our results indicate that patients with NAFLD are characterized by a low-grade systemic inflammation. The high CCL2/MCP-1 levels in NASH might be of importance for the conversion from simple steatosis to NASH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618517     DOI: 10.1016/j.jhep.2006.02.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  193 in total

1.  Assessment of endothelial function in patients with nonalcoholic fatty liver disease.

Authors:  Yasar Colak; Ebubekir Senates; Atakan Yesil; Yusuf Yilmaz; Oguzhan Ozturk; Levent Doganay; Ender Coskunpinar; Ozlem Timirci Kahraman; Banu Mesci; Celal Ulasoglu; Ilyas Tuncer
Journal:  Endocrine       Date:  2012-06-03       Impact factor: 3.633

2.  A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Divya P Kumar; Prasanna K Santhekadur; Mulugeta Seneshaw; Faridoddin Mirshahi; Cora Uram-Tuculescu; Arun J Sanyal
Journal:  Hepatology       Date:  2019-03-04       Impact factor: 17.425

Review 3.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 4.  Nonalcoholic fatty liver disease and cardiovascular disease risk.

Authors:  Roger K Schindhelm; Michaela Diamant; Robert J Heine
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

5.  Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.

Authors:  James P Luyendyk; Bradley P Sullivan; Grace L Guo; Ruipeng Wang
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

6.  Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.

Authors:  Keiko Iwamoto; Keishi Kanno; Hideyuki Hyogo; Sho-Ichi Yamagishi; Masayoshi Takeuchi; Susumu Tazuma; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

Review 7.  Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis.

Authors:  Jacquelyn J Maher; Pablo Leon; James C Ryan
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

Review 8.  Choline's role in maintaining liver function: new evidence for epigenetic mechanisms.

Authors:  Mihai G Mehedint; Steven H Zeisel
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-05       Impact factor: 4.294

9.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

10.  Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.

Authors:  Annie-Carole Tosello-Trampont; Susan G Landes; Virginia Nguyen; Tatiana I Novobrantseva; Young S Hahn
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.